EE03058B1 - Apolipoproteiini molekulaarse teisendi dimeer ja selle valmistamismeetod - Google Patents

Apolipoproteiini molekulaarse teisendi dimeer ja selle valmistamismeetod

Info

Publication number
EE03058B1
EE03058B1 EE9400375A EE9400375A EE03058B1 EE 03058 B1 EE03058 B1 EE 03058B1 EE 9400375 A EE9400375 A EE 9400375A EE 9400375 A EE9400375 A EE 9400375A EE 03058 B1 EE03058 B1 EE 03058B1
Authority
EE
Estonia
Prior art keywords
apolipoprotein
dimer
pct
apo
preparation
Prior art date
Application number
EE9400375A
Other languages
English (en)
Estonian (et)
Inventor
Sirtori Cesare
Franceschini Guido
Abrahms�n Lars
Holmgren Erik
Lake Mats
Lind Peter
Nilsson Bj�rn
Chmielewska Joanna
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of EE03058B1 publication Critical patent/EE03058B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EE9400375A 1991-12-13 1994-11-16 Apolipoproteiini molekulaarse teisendi dimeer ja selle valmistamismeetod EE03058B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9103701A SE9103701D0 (sv) 1991-12-13 1991-12-13 Apolipoprotein

Publications (1)

Publication Number Publication Date
EE03058B1 true EE03058B1 (et) 1997-12-15

Family

ID=20384608

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400375A EE03058B1 (et) 1991-12-13 1994-11-16 Apolipoproteiini molekulaarse teisendi dimeer ja selle valmistamismeetod

Country Status (28)

Country Link
US (2) US5876968A (fr)
EP (1) EP0571602B1 (fr)
JP (1) JPH07502892A (fr)
AT (1) ATE242269T1 (fr)
AU (2) AU3175593A (fr)
BG (1) BG61451B1 (fr)
BR (1) BR9205640A (fr)
CA (1) CA2103996C (fr)
CZ (1) CZ289879B6 (fr)
DE (1) DE69233092T2 (fr)
DK (1) DK0571602T3 (fr)
EE (1) EE03058B1 (fr)
ES (1) ES2199939T3 (fr)
FI (1) FI115771B (fr)
HU (2) HU217203B (fr)
IL (1) IL103956A (fr)
MX (1) MX9207224A (fr)
NO (1) NO315076B1 (fr)
NZ (2) NZ280516A (fr)
PL (3) PL171907B1 (fr)
PT (1) PT571602E (fr)
RO (1) RO115636B1 (fr)
RU (1) RU2134696C1 (fr)
SE (1) SE9103701D0 (fr)
SG (1) SG47453A1 (fr)
SK (1) SK86893A3 (fr)
WO (1) WO1993012143A1 (fr)
ZA (1) ZA928989B (fr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US6258596B1 (en) 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
FR2734568B1 (fr) * 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
DE60117781T2 (de) * 2000-04-21 2006-11-23 Amgen Inc., Thousand Oaks Peptidderivate des apolipoproteins-a1/aii
BRPI0003386B8 (pt) * 2000-08-08 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
BR0115257A (pt) * 2000-11-10 2003-08-12 Proteopharma Aps Análogos de apolipoproteìna
US7217785B2 (en) * 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
PL372925A1 (en) * 2001-09-28 2005-08-08 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
WO2003049685A2 (fr) * 2001-12-07 2003-06-19 The Regents Of The University Of California Traitement de la degenerescence maculaire liee au vieillissement
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
US20100204103A1 (en) * 2002-05-08 2010-08-12 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
BR0310100A (pt) * 2002-05-17 2007-04-27 Esperion Therapeutics Inc métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
JP2006507223A (ja) 2002-05-17 2006-03-02 エスペリオン セラピューティクス，インコーポレイテッド 脂質代謝異常疾患の治療方法
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
WO2005051413A2 (fr) * 2003-11-26 2005-06-09 Novartis Ag Genes associes a une maladie
CA2549529A1 (fr) * 2003-12-15 2005-06-30 The Regents Of The University Of California Peptides synthetiques helicoidaux stimulant la sortie du cholesterol des cellules
JP2007531537A (ja) * 2004-04-06 2007-11-08 セダーズ−シナイ　メディカル　センター アポリポタンパク質ａ−ｉおよびアポリポタンパク質ａ−ｉｍｉｌａｎｏをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
WO2012047930A2 (fr) * 2010-10-04 2012-04-12 The Regents Of The University Of California Compositions et procédés de traitement de cancers gynécologiques
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
MX2007013430A (es) 2005-04-29 2008-03-19 Univ California Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
WO2007000924A1 (fr) * 2005-06-28 2007-01-04 Osaka University Préparation pharmaceutique comprenant une substance susceptible d'inhiber ou de promouvoir l'activité de la progranuline et méthode de criblage pour la recherche d'une substance susceptible d'inhiber ou de promouvoir l'activité de la progranuline
KR100719389B1 (ko) 2005-10-18 2007-05-17 주식회사 녹십자 인간혈장으로부터 아포리포단백질 ａ-ｉ을 분리 정제하는방법
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
AU2007284801A1 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
US9637753B2 (en) * 2006-08-10 2017-05-02 Plantechno S.R.L. In-plant production of oligomeric (comprising three or more units) forms of human Apo A-1 protein muteins
US8541236B2 (en) * 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
WO2009032702A2 (fr) 2007-08-28 2009-03-12 Uab Research Foundation Polypeptides synthétiques analogues d'apolipoprotéine e et procédés d'utilisation
EP2195331B1 (fr) 2007-08-28 2013-11-20 Uab Research Foundation Polypeptides de synthèse imitant l'apolipoprotéine e et leurs procédés d'utilisation
US20100212030A1 (en) * 2007-10-19 2010-08-19 Pronota N.V. Use of n-terminal and c-terminal proteomics technology to enhance protein therapeutics and diagnostics
WO2009055538A1 (fr) 2007-10-23 2009-04-30 The Cleveland Clinic Foundation Apolipoprotéine a-1 résistante aux oxydants et peptides mimétiques
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
CN111808084A (zh) 2008-11-10 2020-10-23 阿布特斯生物制药公司 用于递送治疗剂的新型脂质和组合物
EP3243504A1 (fr) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Formulation lipidique améliorée
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
SG10201911942UA (en) 2009-05-05 2020-02-27 Muthiah Manoharan Lipid compositions
KR101766408B1 (ko) 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
AP2015008874A0 (en) 2009-08-14 2015-11-30 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
EP3296398A1 (fr) 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Nanoparticules pour l'administration d'acide nucléique
RU2553333C2 (ru) * 2009-12-14 2015-06-10 Сцил Протеинс Гмбх Способ идентификации гетеромультимерных модифицированных убиквитиновых белков со способностью связываться с лигандами
EP3494963A1 (fr) 2009-12-18 2019-06-12 The University of British Columbia Procédés et compositions d'administration d'acides nucléiques
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130137628A1 (en) * 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
KR20190039347A (ko) 2010-06-03 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 활성제의 전달을 위한 생분해성 지질
WO2012016184A2 (fr) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour la délivrance d'agents actifs
WO2012016188A2 (fr) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour l'administration d'agents actifs
US20130142760A1 (en) 2010-08-18 2013-06-06 Cedars-Sinai Medical Center Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer
WO2012064824A1 (fr) 2010-11-09 2012-05-18 Alnylam Pharmaceuticals, Inc. Compositions à formulation lipidique et procédés d'inhibition de l'expression des gènes eg5 et vegf
CA2824526C (fr) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Lipides pegyles et leur utilisation pour une administration de medicament
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
CA2837804C (fr) 2011-06-15 2018-03-20 Scil Proteins Gmbh Proteines liantes dimeres obtenues a partir d'ubiquitines modifiees
EP2748191A1 (fr) 2011-08-25 2014-07-02 F.Hoffmann-La Roche Ag Protéine hybride raccourcie tétranectine-apolipoprotéine a-i, particule lipidique la contenant, et utilisations associées
EP3456317B1 (fr) 2011-09-27 2025-09-24 Alnylam Pharmaceuticals, Inc. Lipides di-aliphatiques pegylés substitués
WO2014011908A1 (fr) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Mélanges d'apolipoprotéine
EP2853259A1 (fr) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Composition de lipoprotéines haute densité reconstituées et leurs utilisations
CA2947127A1 (fr) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Marqueurs de therapie hdl
WO2016018665A1 (fr) 2014-07-31 2016-02-04 Uab Research Foundation Peptides e-mimétiques d'apo ayant une puissance supérieure afin de dégager le taux de cholestérol plasmatique
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規なｅｇｆｒ結合タンパク質
JP6856938B2 (ja) 2015-07-16 2021-04-14 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規な免疫グロブリン結合タンパク質およびアフィニティ精製におけるそれらの使用
WO2017013136A1 (fr) 2015-07-20 2017-01-26 Scil Proteins Gmbh Nouvelles protéines de liaison à base de mutéines de di-ubiquitine et procédés de production
US11813336B2 (en) 2016-05-04 2023-11-14 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
CN109963864B (zh) 2016-08-11 2024-01-02 瑞普利金公司 用于亲和色谱的碱性稳定性fc结合蛋白
EP3668600B1 (fr) 2017-08-10 2024-05-15 Abionyx Pharma SA Cargomères
ES2984286T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Apómeros
US11414466B2 (en) 2017-11-07 2022-08-16 Navigo Proteins Gmbh Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
MX2021007283A (es) 2018-12-18 2021-07-15 Navigo Proteins Gmbh Proteinas de union especificas del folr1 novedosas para diagnostico y tratamiento del cancer.
MX2022012969A (es) 2020-04-16 2022-11-09 Abionyx Pharma Sa Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos.
IL301769A (en) 2020-10-01 2023-05-01 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
MX2023012223A (es) 2021-04-15 2023-10-26 Abionyx Pharma Sa Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos.
CN119317440A (zh) 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
JP2025519606A (ja) 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
IL317448A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (fr) 2023-10-31 2025-05-08 Abionyx Pharma Sa Thérapie par molécules à protéine d'ancrage lipidique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein

Also Published As

Publication number Publication date
DE69233092T2 (de) 2004-07-08
NO932866D0 (no) 1993-08-12
RU2134696C1 (ru) 1999-08-20
BG98036A (bg) 1994-05-27
US5876968A (en) 1999-03-02
FI115771B (fi) 2005-07-15
HUT70270A (en) 1995-09-28
US6617134B1 (en) 2003-09-09
BG61451B1 (en) 1997-08-29
CZ289879B6 (cs) 2002-04-17
PT571602E (pt) 2003-10-31
DK0571602T3 (da) 2003-10-06
CA2103996C (fr) 2007-01-16
BR9205640A (pt) 1994-05-03
HU9302344D0 (en) 1994-01-28
EP0571602B1 (fr) 2003-06-04
FI933557A0 (fi) 1993-08-12
MX9207224A (es) 1993-06-01
NO932866L (no) 1993-08-12
SE9103701D0 (sv) 1991-12-13
PL171907B1 (pl) 1997-06-30
NZ280516A (en) 1997-06-24
DE69233092D1 (de) 2003-07-10
IL103956A0 (en) 1993-05-13
PL172544B1 (pl) 1997-10-31
AU5947396A (en) 1996-10-31
HU211667A9 (en) 1995-12-28
ZA928989B (en) 1993-05-17
IL103956A (en) 1998-09-24
WO1993012143A1 (fr) 1993-06-24
CZ158993A3 (en) 1994-07-13
SG47453A1 (en) 1998-04-17
RO115636B1 (ro) 2000-04-28
AU3175593A (en) 1993-07-19
FI933557L (fi) 1993-08-12
JPH07502892A (ja) 1995-03-30
AU703283B2 (en) 1999-03-25
CA2103996A1 (fr) 1993-06-14
ES2199939T3 (es) 2004-03-01
PL172168B1 (pl) 1997-08-29
NZ246223A (en) 1996-06-25
HU217203B (hu) 1999-12-28
EP0571602A1 (fr) 1993-12-01
SK86893A3 (en) 1994-04-06
PL300262A1 (en) 1994-03-07
NO315076B1 (no) 2003-07-07
ATE242269T1 (de) 2003-06-15

Similar Documents

Publication Publication Date Title
EE03058B1 (et) Apolipoproteiini molekulaarse teisendi dimeer ja selle valmistamismeetod
RU93054168A (ru) Димер молекулярного варианта аро-липопротеина, способ его получения, фармацевтическая композиция на его основе
RU2159761C2 (ru) Замещенные 4-биарилмасляные или 5-биарилпентановые кислоты или их производные, способы их получения, фармацевтическая композиция и способ лечения
IL126038A0 (en) Novel benzothiepines and derivatives thereof and pharmaceutical compositions comprising them
PT706398E (pt) Composicao farmaceutica contendo heparina fragmentos de heparina ou seus derivados em combinacao com esteres de glicerol
DK0754048T3 (da) Behandling af partielt væksthormon-insentivitetssyndrom
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
NO962664L (no) Forbindelser med veksthormonfrigjörende egenskaper
DE3684409D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose.
ATE73332T1 (de) Neuartige verwendung von taurolin.
DK0690721T3 (da) Behandling af Mycobakterielle sygdomme ved indgivelse af baktericidt/permeabilitets-forøgende proteinprodukter
EA200200348A1 (ru) Фармацевтические растворы левосимендана
EP0719791A2 (fr) Médicaments pour le traitement de la restenose et de la sclérose artérielle
KR0148213B1 (en) Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same
AU2696584A (en) Pharmaceutical compositions of anti-pancreatic inflammatory effect
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
DK0966455T3 (da) Oxirancarboxylsyrer til behandling af diabetes
ZA954826B (en) New hydrazino and hydroxyamino-14beta-hydroxyandrostane derivatives active on the cardiovascular system processes for their preparation and pharmaceutical compositions containing same
WO1999050286A3 (fr) Peptides antioxydants
SE9301324D0 (sv) New method of treatment
DK0733371T3 (da) Middel til subkutan administrering af protein C
IT1247508B (it) Composizioni farmaceutiche contenenti l'estere 4-(2 metilamminoetil)- 1,2- fenilenicodell`acido 2-metilpropanoico per il trattamento della neurootticopatia glaucomatosa
DK563886A (da) Terapeutisk komposition
IT215302Z2 (it) Tavolo provvisto di porzioni di estremita' sfilabili, disposte inferiormente al suo ripiano e suscettibili di disporsi complanarmente allo stesso.